Latest Breaking News On - Vertice pharma - Page 4 : comparemela.com

Afrezza Quarterly Sales Increase, New Therapies on Horizon at MannKind | San Fernando Valley Business Journal

MannKind Corp. touted increased sales for its flagship drug Afrezza during its fourth quarter earnings report on Thursday, while pointing out its new direction toward therapies for lung and endocrine diseases. During the quarter, MannKind pulled in $10.1 million in revenue for Afrezza, its inhalable insulin, a 30 percent increase compared to sales in the same quarter of 2019. The Westlake Village biotech company reported an adjusted net loss of $13.2 million (-6 cents a share). That’s narrower than the net loss of $14.3 million (-7 cents) in the same period a year earlier. Revenue was $18.4 million, an increase from $16 million the same quarter the previous year.

New jerseyUnited statesMichael castagnaAmy stulickVertice pharmaMannkind corpAfrezza quarterly sales increaseNew therapiesWestlake villageExecutive michael castagnaPennsylvania based qrumpharmaUnited therapeuticsFourth quarterபுதியது ஜெர்சிஒன்றுபட்டது மாநிலங்களில்மைக்கேல் காஸ்டஞ

autoimmune hemolytic anemia treatment Market is Projected to Grow Massively in Near Future – KSU

The autoimmune hemolytic anemia treatment Market research report thoroughly explains each and every aspect related to the Global autoimmune hemolytic anemia treatment Market, which facilitates the report’s reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business. autoimmune hemolytic anemia treatment Market Insight: Global Autoimmune hemolytic anemia Treatment Market is growing at a steady CAGR in the forecast period of 2019-2026. Increasing research and development expenses and high demand of novel therapies are some factors fueling the market growth Avail Your Free Sample Copy of the autoimmune hemolytic anemia treatment Market Report (Including Full TOC, List of Tables & Figures, Chart)@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-autoimmune-hemolytic-anemia-treatment-market

United statesHong kongUnited kingdomSouth africaSaudi arabiaZydus cadilaAsia pacificVertice pharmaRoche ltdTeva pharmaceuticalResearch methodologyIndustries ltdMomenta pharmaceuticals incAlexion pharmaceuticals incRigel pharmaceuticals inc incyte corporationMarket research

Vertice launches THYQUIDITY™ (levothyroxine sodium) Oral Solution

Vertice Pharma ("Vertice"), a specialty pharmaceuticals company focused on improving patients' health, today announced the launch of THYQUIDITY. THYQUIDITY is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism and as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Thyroid glandThyroid hormoneVertice pharmaMannkind corporationதைராய்டு சுரப்பிதைராய்டு ஹார்மோன்

Vertice launches THYQUIDITY™ (levothyroxine sodium) Oral Solution

Vertice launches THYQUIDITY™ (levothyroxine sodium) Oral Solution
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesNew jerseyUnited kingdomJ clin endocrinolScott meyersJohn walshVertice pharmaNutrition examination surveyNational healthMannkind corporation nasdaqCompany media contactKimberly branchVistapharm incChief executive officerMannkind corporationSpecialty sales

Opioids Market Size Worth USD 29,535 Million | 7 12% CAGR By 2023

Opioids Market Size Worth USD 29,535 Million | 7 12% CAGR By 2023
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.

United kingdomSouth koreaBoehringer ingelheim gmbMallinckrodt surreyPurdue pharmaAsia pacificAkash anandSun pharmaceutical industries ltd indiaWard pharmaceuticals corporation jordanAllergan incResearch reportResearch reportsEgalet corporationVertice pharmaMarket research futureJanssen global services